1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
NextCell Pharma AB

NextCell Pharma AB

SSTO:NXTCL
1.00
SEK
+0.04
(+3.65%)
-0.57EPS
120.30MMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.11
0.04
0.05
0.06
0.11
0.09
0.13
0.23
0.26
0.12
0.14
Basic EPS, GAAP
-1.38
-1.53
-1.03
-1.09
-0.63
-0.54
-0.56
-0.82
-0.91
-1.03
-0.46
-0.57
Free Cash Flow per Basic Share
-1.52
-1.51
-1.15
-1.05
-0.67
-0.6
-0.6
-0.94
-1.1
-0.93
- -
-0.55
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.65
0.45
1.48
0.39
0.8
0.79
3.45
2.65
1.74
0.92
0.45
0.37
Tangible Book Value per Share
0.65
0.45
1.48
0.39
0.8
0.79
3.45
2.65
1.74
0.92
0.45
0.37
Basic Weighted Avg Shares
7
7
13
13
29
33
44
44
44
41
85
70
Sales/Revenue/Turnover
- -
1
1
1
2
4
4
6
10
11
10
10
Operating Margin (%)
-149,736.24
-1,412.36
-2,563.96
-2,143.19
-993.32
-496.6
-634.48
-626.68
-405.42
-404.81
-401.3
-407.82
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
3
Net Income, GAAP
-10
-11
-13
-14
-18
-18
-25
-36
-40
-42
-39
-40
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-147,840.73
-1,410.79
-2,560.93
-2,140.98
-993.16
-495.99
-627.73
-636.17
-393.65
-393.45
-395.19
-398.39
Working Capital
7
4
16
2
20
24
143
100
57
51
33
24
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
10
7
19
5
23
26
150
116
76
68
51
41
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-138.04
-102.52
-116.38
-128.55
-71.9
-27.86
-26.77
-41.63
-58.55
-66.59
-90.26

Capital Structure

SEK

•

in mil. unless spec.
Nov'25
Feb'25
May'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
73
73
111
Market Capitalization
128
259
120

Working Capital

SEK

•

in mil. unless spec.
Nov'25
Feb'25
May'25
Total Current Assets
49
41
31
Cash, Cash Equivalents & STI
34
26
17
Accounts Receivable, Net
2
2
2
Inventories
1
1
1
Total Current Liabilities
6
6
7
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
82.64%
75.82%
-25.15%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
15.42%
18.96%
-6.22%
Sales/Revenue/Turnover
1,191.99%
26.48%
-6.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
2
2
3
3
10
2024
4
2
2
2
11
2025
3
3
2
2
10

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.2
-0.26
-0.32
-0.2
-0.91
2024
-0.28
-0.29
-0.26
-0.22
-1.03
2025
-0.11
-0.11
-0.14
-0.12
-0.46

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mathias Svahn
Full Time Employees
24
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Karolinska Institutet Science Park Huddinge AB Sweden 141 57
IPO Date
Jul 13, 2017
Website
nextcellpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
NextCell Pharma AB (NXTCL.ST) develops and commercializes mesenchymal stromal cell therapies derived from umbilical cord tissue for autoimmune and inflammatory diseases; its lead product candidate ProTrans employs a patented selection algorithm to optimize cells for type 1 diabetes treatment, preserving insulin production as demonstrated in clinical trials, with potential applications in Crohn's disease, multiple sclerosis and rheumatism; the company also operates Cellaviva, Scandinavia's largest private stem cell bank for family preservation of umbilical cord blood and tissue stem cells, and offers QVance quality assurance services for advanced therapy developers; additionally, NextCell provides research-use-only umbilical cord MSC products manufactured in-house. NextCell Pharma AB, founded in 2014 and headquartered at Karolinska Institutet Science Park in Huddinge, Sweden, conducts operations primarily in the Nordic region with subsidiaries Cellaviva AB, QVance AB and an 8.5% stake in FamicordTx. Recent developments include a December 2025 collaboration with OptiCell Solutions AB for cell handling, freezing, storage and transport to expand service revenue and leverage infrastructure; a strategic partnership with FUJIFILM Biosciences Inc. to integrate its MSC products with PRIME-XV media for research acceleration; the November 2025 appointment of Eric Gustafsson as CFO effective December 15 to support industrial scaling and expansion; and publication of Interim Report 4 for June-August 2025 reflecting a shift to a January-December fiscal year.